Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High - Here's Why

Key Points

• Generate Biomedicines shares surged 20.2%, reaching a new 52-week high of $18.41 and giving the company a market capitalization of approximately $2.73 billion.
• Analyst sentiment is broadly positive, with six Buy ratings, one Hold and one Sell; the stock has a “Moderate Buy” consensus rating and a $25.40 average price target.
• The company reported quarterly revenue of $6.31 million but missed earnings estimates, posting an EPS loss of $0.52 versus the expected $0.48 loss. Institutional interest increased after Braidwell LP established a roughly $55.4 million position.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $18.41 and last traded at $18.6240, with a volume of 199688 shares. The stock had previously closed at $17.72.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GENB. HC Wainwright boosted their target price on Generate Biomedicines from $16.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, May 8th. Wall Street Zen lowered Generate Biomedicines from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Weiss Ratings assumed coverage on Generate Biomedicines in a research note on Tuesday, August 11th. They issued a "sell (d)" rating on the stock. Finally, Morgan Stanley upped their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Generate Biomedicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.40.

Generate Biomedicines Trading Up 20.2%

The company has a market capitalization of $2.73 billion and a P/E ratio of -13.76. The company has a 50-day moving average price of $15.05.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. On average, research analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Braidwell LP acquired a new position in Generate Biomedicines in the second quarter valued at about $55,398,000. Bank of New York Mellon Corp acquired a new stake in shares of Generate Biomedicines during the second quarter worth approximately $967,000. AXQ Capital LP acquired a new stake in shares of Generate Biomedicines during the second quarter worth approximately $218,000. Susquehanna International Group LLP bought a new position in shares of Generate Biomedicines in the second quarter valued at approximately $196,000. Finally, California State Teachers Retirement System acquired a new position in shares of Generate Biomedicines in the 2nd quarter worth approximately $96,000.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source